Clinical investigation into the pathophysiology of systemic sclerosis (SSc) identified a pathologic subset of CD8 T cells polarized to produce IFN-gamma and IL-13 upon activation. Tmem273 is a cell surface glycoprotein directly linked to the production of IL-13 in the subset of CD8 T cells polarized in that fashion. We humanized monoclonal antibodies against human Tmem273 as therapeutic depleting biologics and have a murinized antibody specific for mouse Tmem273 to enable a mouse preclinical depletion model. We are seeking funds to characterize the recombinant antibodies, do a small human SSc investigation, and develop the mouse model.